New blood test a boon to clot research

PhD student Hannah Pearce with Dr Thomas
Bonnard, first author on the paper describing
a new test for measuring thrombolytic activity

by Anne Crawford

Monash University researchers have developed a novel blood assay that is proving highly effective in researching thrombosis (blood clotting) and which could potentially become a valuable tool in clinical translation.

Heart attack and stroke – leading causes of death and disability in Australia – are mostly caused by thrombosis. Researchers around the world are striving to improve anti-thrombotic treatments that counter the life-threatening blood clots without the associated side-effect of excessive bleeding.

EMCR news: Thomas Bonnard profiled in The Limbic

Dr Thomas Bonnard is a research fellow in Dr Christoph Hagemeyer's Nanobiotechnology laboratory of the Australian Centre for Blood Diseases. He is funded by a William Harvey Translational Research Fellowship from the European Union. He was recently profiled by thelimbic.com for his work, in his own words, on "improv[ing]heart disease treatment with nanomedical devices."

See more: Designer molecule offers targeted thrombolysis at the site of blood clots

Congratulations to Thomas Bonnard for the ISFP D. Collen Young Investigator Award!

Thomas Bonnard (pictured) from Dr Christoph Hagemeyer's lab recently won a prestigious D. Collen Young Investigator Award. It is awarded every two years by the International Society for Fibrinolysis and Proteolysis (ISFP) to honour the contributions of Désiré Collen to research on fibrinolysis, proteolysis and thrombolysis, at the occasion of the congress of the ISFP.

See more about the research at:
www.acbd.monash.org/research/hagemeyer.html